



COPY OF PAPERS US-200.6246.200
ORIGINALLY FILED
Attorney Docket No.: 6246.200.200

0300 #6
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: P. Serup et al

Serial No.: 10/090,011

Group Art Unit: To be assigned

Filed: February 26, 2002

Examiner: To be assigned

Confirmation No: 3868

For: Methods for Generating Insulin-Secreting Cells Suitable For Transplantation

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (4 Total)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents
Washington, DC 20231

On May 13, 2002.

Sylvia Gonzalez

(name of person mailing paper)

Sylvia Gonzalez
(signature of person mailing paper)



Attorney Docket No.: 5246.200-US

ORIGINALIALLY FILED
COPY OF PAPERS

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: P. Serup et al

Application No.: 10/090,011

Group Art Unit: To be assigned

Filed: February 26, 2002

Examiner: To be assigned

Confirmation No: 3868

For: Methods for Generating Insulin-Secreting Cells Suitable For Transplantation

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. S.B. Weir et al., "*In vitro* cultivation of human islets from expanded ductal tissue" PNAS, Vol. 97., No. 14., pgs. 7999-8004 (2000)

2. Gerard Gradwohl et al. *Neurogenin3* is required for the development of the four endocrine cell lineages of the pancreas" PNAS., Vol., 97., No. 4., pgs. 1607-1611 (2000)
3. U.S. Patent No. 6,001,647
4. WO 00/47720

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: May 13, 2002

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650
PATENT TRADEMARK OFFICE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.